CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Philadelphia, Pennsylvania, United States and 7 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 56 other locations
NMS-03597812 as single agent in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients who have exhausted standard treatment, includi...
Phase 1
Newark, Delaware, United States and 6 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Bethlehem, Pennsylvania, United States and 108 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Philadelphia, Pennsylvania, United States and 43 other locations
chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Venetoclax and azacitidine (inve...
Phase 2
Philadelphia, Pennsylvania, United States and 8 other locations
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogene...
Phase 1
Philadelphia, Pennsylvania, United States
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Philadelphia, Pennsylvania, United States and 110 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes l...
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 19 other locations
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....
Phase 1, Phase 2
Philadelphia, Pennsylvania, United States and 38 other locations
Clinical trials
Research sites
Resources
Legal